Drug Profile
Oltipraz - PharmaKing
Alternative Names: PMK-N01GI1Latest Information Update: 12 Oct 2022
Price :
$50
*
At a glance
- Originator PharmaKing
- Class Chemoprotectants; Organic sulfur compounds; Pyrazines; Small molecules
- Mechanism of Action Glutathione transferase stimulants; Liver X receptor antagonists; NQO1 stimulants; Ribosomal protein S6 kinase modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Non-alcoholic fatty liver disease
Most Recent Events
- 26 Sep 2022 PharmaKing completes a phase III trial in Non-alcoholic fatty liver disease (In adults, In the elderly) in South Korea (PO) (NCT04142749)
- 15 Nov 2019 PharmaKing initiates a phase III trial for Non-alcoholic fatty liver disease (In adults, In the elderly) in South Korea (PO) (NCT04142749)
- 29 Oct 2019 PharmaKing plans a phase III trial in Non-alcoholic fatty liver disease (In adults, In the elderly) in October 2019 (NCT04142749)